SEC Form 4
Pacira BioSciences, Inc. (PCRX) insider trading
In the 12 months to Nov 16, 2026, 5 PCRX insiders reported open-market sales of $2.5M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $2.5M
- 13 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 12 of 13
- $2.5M of $2.5M sold (100%)
Who traded PCRX, and when
- Sale
- Sale, pre-arranged (10b5-1)
PCRX daily close from Nov 17, 2025 to Nov 16, 2026, between $19.16 and $36.49, last $36.48. 13 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Shawn Cross, Chief Financial Officer: sold $1.3M across 3 filings, first filed Dec 11, 2025, last Apr 24, 2026. Kristen Williams, Chief Administrative Officer: sold $498.2K across 2 filings, first filed Feb 3, 2026, last Jun 5, 2026. Lauren Riker, Senior Vice President, Finance: sold $479.2K across 4 filings, first filed Jan 6, 2026, last Oct 9, 2026. Jonathan Slonin, Chief Medical Officer: sold $240.4K across 3 filings, first filed Nov 19, 2025, last Aug 18, 2026. Mark Froimson, Director: sold $10.9K across 1 filing, first filed Mar 19, 2026, last Mar 19, 2026.
Largest mark · tap a row for others
Shawn Cross · Chief Financial Officer
Filing 1 of 2 within a week · $628,194 total
Sale $302,598
12,059 shares at $25.09 avg
Filed Apr 22, 2026 · traded Apr 20
Pre-arranged (10b5-1) · close on filing date $24.88
Shawn Cross · Chief Financial Officer
Chief Financial Officer
$1.3M soldKristen Williams · Chief Administrative Officer
Chief Administrative Officer
$498.2K soldLauren Riker · Senior Vice President, Finance
Senior Vice President, Finance
$479.2K soldJonathan Slonin · Chief Medical Officer
Chief Medical Officer
$240.4K soldMark Froimson · Director
Director
$10.9K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Shawn Cross | Chief Financial Officer | $1.3M | — | 3 | 100% of sales | |
| Kristen Williams | Chief Administrative Officer | $498.2K | — | 2 | 100% of sales | |
| Lauren Riker | Senior Vice President, Finance | $479.2K | — | 4 | 100% of sales | |
| Jonathan Slonin | Chief Medical Officer | $240.4K | — | 3 | 100% of sales | |
| Mark Froimson | Director | $10.9K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Lauren Riker Senior Vice President, Finance | SalePre-arranged (10b5-1) | 6,000 | $36.32 | $217.9K | 62,284 | |
traded | Jonathan Slonin Chief Medical Officer | SalePre-arranged (10b5-1) | 3,040 | $23.23 | $70.6K | 216,384 | |
traded | Lauren Riker Senior Vice President, Finance | SalePre-arranged (10b5-1) | 6,115 | $23.50 | $143.7K | 62,284 | |
traded | Kristen Williams Chief Administrative Officer | SalePre-arranged (10b5-1) | 10,259 | $22.27 | $228.5K | 167,062 | |
traded | Shawn Cross Chief Financial Officer | SalePre-arranged (10b5-1) | 12,941 | $25.16 | $325.6K | 105,341 | |
traded | Shawn Cross Chief Financial Officer | SalePre-arranged (10b5-1) | 12,059 | $25.09 | $302.6K | 105,341 | |
traded | Mark Froimson Director | Sale | 500 | $21.81 | $10.9K | 20,136 | |
traded | Jonathan Slonin Chief Medical Officer | SalePre-arranged (10b5-1) | 3,261 | $22.82 | $74.4K | 223,640 | |
traded | Kristen Williams Chief Administrative Officer | SalePre-arranged (10b5-1) | 13,137 | $20.53 | $269.7K | 131,303 | |
traded | Lauren Riker Senior Vice President, Finance | SalePre-arranged (10b5-1) | 4,000 | $20.81 | $83.2K | 52,313 | |
traded | Lauren Riker Senior Vice President, Finance | SalePre-arranged (10b5-1) | 1,416 | $24.24 | $34.3K | 59,064 | |
traded | Shawn Cross Chief Financial Officer | SalePre-arranged (10b5-1) | 25,000 | $25.07 | $626.8K | 56,250 | |
traded | Jonathan Slonin Chief Medical Officer | SalePre-arranged (10b5-1) | 3,960 | $24.09 | $95.4K | 178,367 |
GET /stocks/filings/vX/form-4?tickers=PCRX&filing_date.gte=2025-11-16&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"PCRX"
],
"issuer_cik": "0001396814",
"owner_cik": "0001545439",
"accession_number": "0001628280-26-065566",
"form_type": "4",
"filing_date": "2026-10-09",
"period_of_report": "2026-10-08",
"issuer_name": "Pacira BioSciences, Inc.",
"issuer_trading_symbol": "PCRX",
"owner_name": "RIKER LAUREN",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Senior Vice President, Finance",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 6000,
"transaction_price_per_share": 36.32,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 62284.242,
"transaction_value": 217920,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026."
}
]
},
{
"tickers": [
"PCRX"
],
"issuer_cik": "0001396814",
"owner_cik": "0001875723",
"accession_number": "0001628280-26-057759",
"form_type": "4",
"filing_date": "2026-08-18",
"period_of_report": "2026-08-17",
"issuer_name": "Pacira BioSciences, Inc.",
"issuer_trading_symbol": "PCRX",
"owner_name": "SLONIN JONATHAN",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Medical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-17",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 3040,
"transaction_price_per_share": 23.23,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 216383.646,
"transaction_value": 70619.2,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025."
},
{
"id": "F2",
"description": "Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 34 records
- Option exercises7 records
- Tax withholding12 records
- Grants and awards15 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Pacira BioSciences, Inc.'s CEO sold stock?
No. Frank D. Lee (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is PCRX’s insider data?
These are PCRX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track PCRX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for PCRX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.